ASND vs INCY vs IONS vs ALKS vs LLY

For growth investors, Ascendis Pharma A/S (ASND) is the stronger pick with 90.

2% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Incyte Corporation (INCY) offers the better valuation at 15. 3x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate Ascendis Pharma A/S (ASND) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Incyte Corporation (INCY) is the cheapest at 15.

3x versus Eli Lilly and Company at 42. 5x. On forward P/E, Incyte Corporation is actually cheaper at 13. 1x.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +411.

1%, compared to +18. 2% for Incyte Corporation (INCY). Over 10 years, the gap is even starker: ASND returned +1451% versus ALKS's -11. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ascendis Pharma A/S (ASND) is the lower-risk stock at 0.

33β versus Alkermes plc's 1. 06β — meaning ALKS is approximately 221% more volatile than ASND relative to the S&P 500. On balance sheet safety, Incyte Corporation (INCY) carries a lower debt/equity ratio of 1% versus 5% for Ionis Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ascendis Pharma A/S (ASND) is pulling ahead at 90.

2% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Incyte Corporation grew EPS 41. 7% year-over-year, compared to -34. 1% for Alkermes plc. Over a 3-year CAGR, ASND leads at 138. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Eli Lilly and Company (LLY) is the more profitable company, earning 31.

7% net margin versus -40. 4% for Ionis Pharmaceuticals, Inc. — meaning it keeps 31. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -40. 5% for IONS. At the gross margin level — before operating expenses — IONS leads at 98. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Incyte Corporation (INCY) trades at 13.

1x forward P/E versus 61. 8x for Ascendis Pharma A/S — 48. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for IONS: 41. 1% to $107. 27.

In this comparison, LLY (0.

6% yield) pays a dividend. ASND, INCY, IONS, ALKS do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

71), 0. 6% yield, +1238% 10Y return). Both have compounded well over 10 years (LLY: +1238%, ALKS: -11. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ASND is a mid-cap high-growth stock; INCY is a mid-cap high-growth stock; IONS is a mid-cap high-growth stock; ALKS is a small-cap quality compounder stock; LLY is a large-cap high-growth stock. LLY pays a dividend while ASND, INCY, IONS, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.